RT Journal Article
SR Electronic
T1 Facile Filtration-Based Workflow for Facilitating Sensitive Detection of Pathogenic Bacteria from Blood
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.11.17.23298597
DO 10.1101/2023.11.17.23298597
A1 Park, Dong Jin
A1 Chen, Liben
A1 Wu, Tianqi
A1 Lee, Pei-Wei
A1 Hsieh, Kuangwen
A1 Wang, Tza-Huei
YR 2023
UL http://medrxiv.org/content/early/2023/11/18/2023.11.17.23298597.abstract
AB Bloodstream infections (BSIs) are a global health concern, contributing to high mortality rates and increased healthcare costs. Current diagnostic methods, such as blood culture, matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS), immunoassays, and nucleic acid amplification tests (NAATs), have lengthy workflow bottlenecked by the need of culture based method This study introduces an innovative blood processing method that overcomes this limitation, enabling rapid and culture-free isolation of pathogenic bacteria from whole blood. The method combines osmolysis, blood separation membrane filtration, detergent and enzymatic lysis, and bacterial capture, requiring minimal specialized equipment. Notably, it uses a small blood sample volume (0.5 mL or below), making it suitable for pediatric patients. The workflow involves four simple steps and can be completed in approximately 30 minutes, providing rapid pathogen isolation. The protocol was successfully tested with two most common causative bacteria, S. aureus and E. coli, achieving sensitive detection down to approximately 10 CFU using benchtop PCR. The culture-free approach accelerates the diagnosis process and minimizes the risk of bacterial population alterations during culturing. While further optimization and testing with a broader range of pathogens are needed, this method holds promise in advancing the diagnosis of life-threatening bacterial infections. Future applications may include rapid point-of-care testing in resource-limited settings.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by NIH grant (R01AI137272). Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.